跳到正文
MarketHOT
English
摘要
SEC · EDGAR 财务披露·· 12 天前AI 评分19

Iovance Biotherapeutics 更新企业演示材料并提交 8-K

IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Filer)

AI 导读

Iovance Biotherapeutics 于 11 月 5 日更新用于医疗保健会议及面向分析师、现有股东等群体的企业演示材料,并提交 Form 8-K。演示文稿作为附件 99.1 纳入文件。

正文

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 05, 2026

IOVANCE BIOTHERAPEUTICS, INC.

(Exact name of Registrant as Specified in its Charter)

Delaware

001-36860

75-3254381

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

300 Rouse Blvd.

Philadelphia, Pennsylvania

19112

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s Telephone Number, Including Area Code: 650 260-7120

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

Trading
Symbol(s)


Name of each exchange on which registered

Common Stock, par value $0.000041666

IOVA

The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Item 8.01 Other Events.

On November 5, 2026, Iovance Biotherapeutics, Inc. (the “Company”) updated its corporate presentation that it uses for presentations at healthcare conferences and to analysts, current stockholders, and others. A copy of the Company’s presentation that it intends to use at such events is attached as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit
No.

Description

99.1

Iovance Biotherapeutics, Inc., Corporate Presentation – November 2026

104

Cover Page Interactive Data File (embedded as Inline XBRL document)


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Iovance Biotherapeutics, Inc.

Date:

November 5, 2026

By:

/s/ Frederick G. Vogt

Name: Frederick G. Vogt, Ph.D., J.D.
Title: Interim CEO and President, and General Counsel


来源:SEC EDGAR · 本站存档